RoosterBio Inc.
Edit

RoosterBio Inc.

https://www.roosterbio.com/
Last activity: 02.05.2024
Categories: LivingMarketProductTechnologyTimeDevelopmentEngineeringHealthTechHumanIndustry
RoosterBio is focused on building a robust and sustainable Regenerative Medicine industry. Our products are designed for Tissue Engineers, Cell Therapists and those developing technologies, products and devices that incorporate living cells. Our products are high quality, affordable, standardized cells and media, manufactured and delivered in formats that simplify research and product development efforts. RoosterBio products will accelerate clinical translation of cell therapies and tissue engineering technologies and shorten time to market of such technologies, thereby benefitting healthcare providers and their patients. We seek to democratize cell culture for the masses and our Twitter feed, Facebook page, website (www.roosterbio.com), and soon-to-be-released blog look to help educate people on industry trends, cell culture, and science in general. We hope to thereby further the fields of Tissue Engineering and Regenerative Medicine by educating and enabling the next wave of top-notch scientists!
Likes
509
Followers
5.75K
Website visits
14.3K /mo.
Mentions
32
Location: United States, Maryland, Ballenger Creek
Employees: 51-200
Phone: +1 301-200-5366
Total raised: $36.75M
Founded date: 2013

Investors 4

Funding Rounds 3

DateSeriesAmountInvestors
11.09.2019Series B$21.5M-
07.08.2019Series B$15MDynamk Cap...
25.02.2014Seed$250K-

Mentions in press and media 32

DateTitleDescription
02.05.2024BioSolution Designs and RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic DevelopmentFREDERICK, MARYLAND, UNITED STATES, May 2, 2024 /EINPresswire.com/ -- BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic...
26.04.2023NanoFCM Partners with RoosterBio as an Approved Service Provider for Exosome AnalysisThe in-depth knowledge and expertise in EV characterization provided by RoosterBio will allow new and existing EV platforms to thrive in this exciting field.” — Ben Peacock, Head of Research for NanoFCM Co., Ltd. FREDERICK, MD, USA, April 2...
13.03.2023RoosterBio and Repligen Collaborate to Advance Scalable Exosome BioprocessingWe are thrilled to partner with Repligen to accelerate our customers’ path to the clinic and enable successful commercialization of innovative exosome therapies.” — Tim Kelly, Chief Executive Officer of RoosterBio FREDERICK, MD, UNITED STAT...
13.03.2023RoosterBio and Repligen Collaborate to Advance Scalable Exosome Bioprocessing"We are thrilled to partner with Repligen to accelerate our customers’ path to the clinic and enable successful commercialization of innovative exosome therapies.” - Tim Kelly, Chief Executive Officer, RoosterBio FREDERICK, Md. (PRWEB)...
25.10.2022FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to Enable GMP Manufacturing of Cell and Exosome Therapies"Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to partner with FUJIFILM Diosynth Biotechnologies to translate our MSC and exosome technologies into advanced therapy product...
24.10.2022FUJIFILM Diosynth Biotechnologies & RoosterBio Collaborate to Enable GMP Manufacturing of Cell & Exosome TherapiesThis collaboration will enable us to become a fully integrated cell therapy CDMO partner to our biopharma customers.” — Gerry Farrell, chief operating officer, FUJIFILM Diosynth Biotechnologies COLLEGE STATION, TEXAS, UNITED STATES, October...
30.08.2022RoosterBio and MBL Beijing Biotech Partner to Accelerate Advanced Therapy Manufacturing in China“RoosterBio’s engineered media products are creating transformative impact for cell and exosome therapy developers all over the world." - Tim Kelly, CEO, RoosterBio FREDERICK, Md. (PRWEB) August 30, 2022 RoosterBio, Inc., a leading sup...
18.08.2022RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies“AGC Biologics has an outstanding track record of success in the manufacture of clinical and commercial advanced therapies and an ever-expanding global network to meet the needs of our customers.” - Tim Kelly, CEO, RoosterBio FREDERICK, Md....
16.08.2022RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome TherapiesRoosterBio and AGC Biologics Announce Collaboration New partnership delivers clinically proven products and manufacturing processes for advanced therapies SEATTLE, WASHINGTON, UNITED STATES, August 16, 2022 /EINPresswire.com/ -- AGC Biologi...
26.04.2022ShiftBio partners with RoosterBio to accelerate development of a novel genetically engineered exosome, SBI-102 for rare diseases and cancer"The opportunity to forge a true collaboration and create this kind of impact to accelerate advanced therapies to patients is what drives our entire organization.” - Tim Kelly, CEO, RoosterBio FREDERICK, Md. (PRWEB) April 26, 2022 Shif...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In